By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics today said that its full-year 2009 revenues increased 65 percent as the firm entered into its commercial phase through the launch of colorectal cancer tests.

The German molecular diagnostics firm reported full-year revenues of €4.3 million ($5.8 million), up 65 percent from €2.6 million for FY 2008.

Its loss before interest and tax was €10.2 million versus a loss of €12.8 million for 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.